Factors, enablers and challenges for COVID-19 vaccine development
The COVID-19 pandemic triggered a sense of vulnerability and urgency that led to concerted actions by governments, funders, regulators and industry to overcome traditional challenges for the development of vaccine candidates and to reach authorisation. Unprecedented financial investments, massive de...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-06-01
|
| Series: | BMJ Global Health |
| Online Access: | https://gh.bmj.com/content/8/6/e011879.full |
| _version_ | 1797756180935737344 |
|---|---|
| author | Peter J Hotez Lois Privor-Dumm Melanie Saville Jerome H Kim Sarah Gilbert Salim Abdool-Karim Didi Thompson Jean-Louis Excler |
| author_facet | Peter J Hotez Lois Privor-Dumm Melanie Saville Jerome H Kim Sarah Gilbert Salim Abdool-Karim Didi Thompson Jean-Louis Excler |
| author_sort | Peter J Hotez |
| collection | DOAJ |
| description | The COVID-19 pandemic triggered a sense of vulnerability and urgency that led to concerted actions by governments, funders, regulators and industry to overcome traditional challenges for the development of vaccine candidates and to reach authorisation. Unprecedented financial investments, massive demand, accelerated clinical development and regulatory reviews were among the key factors that contributed to accelerating the development and approval of COVID-19 vaccines. The rapid development of COVID-19 vaccines benefited of previous scientific innovations such as mRNA and recombinant vectors and proteins. This has created a new era of vaccinology, with powerful platform technologies and a new model for vaccine development. These lessons learnt highlight the need of strong leadership, to bring together governments, global health organisations, manufacturers, scientists, private sector, civil society and philanthropy, to generate innovative, fair and equitable access mechanisms to COVID-19 vaccines for populations worldwide and to build a more efficient and effective vaccine ecosystem to prepare for other pandemics that may emerge. With a longer-term view, new vaccines must be developed with incentives to build expertise for manufacturing that can be leveraged for low/middle-income countries and other markets to ensure equity in innovation, access and delivery. The creation of vaccine manufacturing hubs with appropriate and sustained training, in particular in Africa, is certainly the way of the future to a new public health era to safeguard the health and economic security of the continent and guarantee vaccine security and access, with however the need for such capacity to be sustained in the interpandemic period. |
| first_indexed | 2024-03-12T17:56:50Z |
| format | Article |
| id | doaj.art-c60cd7d6c7bb46068a2dfbdc2736279f |
| institution | Directory Open Access Journal |
| issn | 2059-7908 |
| language | English |
| last_indexed | 2024-03-12T17:56:50Z |
| publishDate | 2023-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Global Health |
| spelling | doaj.art-c60cd7d6c7bb46068a2dfbdc2736279f2023-08-02T13:30:06ZengBMJ Publishing GroupBMJ Global Health2059-79082023-06-018610.1136/bmjgh-2023-011879Factors, enablers and challenges for COVID-19 vaccine developmentPeter J Hotez0Lois Privor-Dumm1Melanie Saville2Jerome H Kim3Sarah Gilbert4Salim Abdool-Karim5Didi Thompson6Jean-Louis Excler7Texas Children`s Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, USAInternational Vaccine Access Center, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USAVaccine Development, Coalition for Epidemic Preparedness Innovations, London, UKInternational Vaccine Institute, Seoul, South KoreaNuffield Department of Medicine, Oxford University, Oxford, UKDepartment of Epidemiology, Columbia University, New York, New York, USAWorld Innovation Summit for Health (WISH), Qatar Foundation, Doha, QatarDirector General`s Office, International Vaccine Institute, Seoul, Korea (the Republic of)The COVID-19 pandemic triggered a sense of vulnerability and urgency that led to concerted actions by governments, funders, regulators and industry to overcome traditional challenges for the development of vaccine candidates and to reach authorisation. Unprecedented financial investments, massive demand, accelerated clinical development and regulatory reviews were among the key factors that contributed to accelerating the development and approval of COVID-19 vaccines. The rapid development of COVID-19 vaccines benefited of previous scientific innovations such as mRNA and recombinant vectors and proteins. This has created a new era of vaccinology, with powerful platform technologies and a new model for vaccine development. These lessons learnt highlight the need of strong leadership, to bring together governments, global health organisations, manufacturers, scientists, private sector, civil society and philanthropy, to generate innovative, fair and equitable access mechanisms to COVID-19 vaccines for populations worldwide and to build a more efficient and effective vaccine ecosystem to prepare for other pandemics that may emerge. With a longer-term view, new vaccines must be developed with incentives to build expertise for manufacturing that can be leveraged for low/middle-income countries and other markets to ensure equity in innovation, access and delivery. The creation of vaccine manufacturing hubs with appropriate and sustained training, in particular in Africa, is certainly the way of the future to a new public health era to safeguard the health and economic security of the continent and guarantee vaccine security and access, with however the need for such capacity to be sustained in the interpandemic period.https://gh.bmj.com/content/8/6/e011879.full |
| spellingShingle | Peter J Hotez Lois Privor-Dumm Melanie Saville Jerome H Kim Sarah Gilbert Salim Abdool-Karim Didi Thompson Jean-Louis Excler Factors, enablers and challenges for COVID-19 vaccine development BMJ Global Health |
| title | Factors, enablers and challenges for COVID-19 vaccine development |
| title_full | Factors, enablers and challenges for COVID-19 vaccine development |
| title_fullStr | Factors, enablers and challenges for COVID-19 vaccine development |
| title_full_unstemmed | Factors, enablers and challenges for COVID-19 vaccine development |
| title_short | Factors, enablers and challenges for COVID-19 vaccine development |
| title_sort | factors enablers and challenges for covid 19 vaccine development |
| url | https://gh.bmj.com/content/8/6/e011879.full |
| work_keys_str_mv | AT peterjhotez factorsenablersandchallengesforcovid19vaccinedevelopment AT loisprivordumm factorsenablersandchallengesforcovid19vaccinedevelopment AT melaniesaville factorsenablersandchallengesforcovid19vaccinedevelopment AT jeromehkim factorsenablersandchallengesforcovid19vaccinedevelopment AT sarahgilbert factorsenablersandchallengesforcovid19vaccinedevelopment AT salimabdoolkarim factorsenablersandchallengesforcovid19vaccinedevelopment AT didithompson factorsenablersandchallengesforcovid19vaccinedevelopment AT jeanlouisexcler factorsenablersandchallengesforcovid19vaccinedevelopment |